Physician profile

Mark T Dransfield

Critical Care Medicine (Internal Medicine) · Birmingham, AL

NPI 1770526725

$160,092.09

in general payments reported to CMS, 2019-2025

14 companies · $134 in 2025

The $134 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).

See the full distribution for Critical Care Medicine (Internal Medicine)

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$19,824.65
Consulting Fee$8,722.00
Food and Beverage$294.29

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $99,931.65 2019-2024 Trelegy Ellipta, Nucala
Teva Pharmaceuticals USA, INC. $17,985.00 2020
Astrazeneca Ab $15,134.06 2019-2021
Astrazeneca Uk Limited $13,725.00 2019
Astrazeneca Pharmaceuticals LP $5,123.89 2019-2024
Genentech, INC. $3,951.45 2023
Pulmonx Corporation $1,915.26 2019-2023 Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter
Novartis Pharmaceuticals Corporation $1,862.00 2021
F. Hoffmann-La Roche Ag $330.00 2024
Verona Pharma, INC. $133.78 2025 Ohtuvayre

4 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$3,281.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark T Dransfield

$160,092.09

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $134 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).

https://glasscript.com/doctor/1182048/mark-t-dransfield

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.